Following consultation with the U.S. Food and Drug Administration (FDA), Eisai has initiated a Phase 3 clinical trial…
Articles by Marisa Wexler, MS
The United Kingdom Home Office has changed the classification of GW Pharmaceuticals‘ Epidyolex — a treatment for epileptic…
Stoke Therapeutics plans to begin enrollment later this year of Dravet syndrome patients for part A of its…
Heart abnormalities are unlikely to be the reason behind the high rate of Sudden Unexpected Death in Epilepsy (SUDEP)…
A newly developed artificial intelligence (AI) system could help expedite the diagnosis of epileptic conditions such as Dravet syndrome.
The United States Food and Drug Administration (FDA) has approved Valtoco (diazepam nasal spray) as a rescue treatment…
Since Jan. 6, physicians in England are able to prescribe the oral cannabidiol solution Epidyolex…
StrideBio and Sarepta Therapeutics announced a collaboration and license agreement to advance gene therapies for rare diseases of the…
The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol…
The first patient has been enrolled in the BUTTERFLY study, which aims to characterize features of Dravet syndrome in children…